361 related articles for article (PubMed ID: 31995597)
21. Cost-effectiveness of pneumococcal vaccines for adults in the United States.
Chen J; O'Brien MA; Yang HK; Grabenstein JD; Dasbach EJ
Adv Ther; 2014 Apr; 31(4):392-409. PubMed ID: 24718851
[TBL] [Abstract][Full Text] [Related]
22. A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult.
Ngamprasertchai T; Kositamongkol C; Lawpoolsri S; Rattanaumpawan P; Luvira V; Chongtrakool P; Kaewkungwal J; Chokephaibulkit K; Phisalprapa P
Front Public Health; 2023; 11():1071117. PubMed ID: 37457251
[TBL] [Abstract][Full Text] [Related]
23. Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland.
Owusu-Edusei K; Favre-Bulle A; Tsoumani E; Mutschler T; Cossrow N
Vaccine; 2024 May; 42(13):3239-3246. PubMed ID: 38609806
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan.
Nakamura S; Mikami M; Hayamizu T; Yonemoto N; Moyon C; Gouldson M; Crossan C; Vietri J; Kamei K
Expert Rev Vaccines; 2024; 23(1):546-560. PubMed ID: 38703180
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan.
Shinjoh M; Togo K; Hayamizu T; Yonemoto N; Morii J; Perdrizet J; Kamei K
Expert Rev Vaccines; 2024; 23(1):485-497. PubMed ID: 38682661
[TBL] [Abstract][Full Text] [Related]
27. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context?
Kulpeng W; Leelahavarong P; Rattanavipapong W; Sornsrivichai V; Baggett HC; Meeyai A; Punpanich W; Teerawattananon Y
Vaccine; 2013 Jun; 31(26):2839-47. PubMed ID: 23588084
[TBL] [Abstract][Full Text] [Related]
28. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults.
Smith KJ; Wateska AR; Nowalk MP; Raymund M; Lee BY; Zimmerman RK
Am J Prev Med; 2013 Apr; 44(4):373-381. PubMed ID: 23498103
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia.
Ordóñez JE; Orozco JJ
BMC Infect Dis; 2014 Mar; 14():172. PubMed ID: 24679135
[TBL] [Abstract][Full Text] [Related]
30. An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Hum Vaccin Immunother; 2019; 15(4):863-872. PubMed ID: 30633706
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.
Zhang XH; Leeuwenkamp O; Oh KB; Lee YE; Kim CM
Hum Vaccin Immunother; 2018 Jan; 14(1):85-94. PubMed ID: 29115905
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program.
Stoecker C; Kobayashi M; Matanock A; Cho BH; Pilishvili T
Vaccine; 2020 Feb; 38(7):1770-1777. PubMed ID: 31889609
[TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.
Sibak M; Moussa I; El-Tantawy N; Badr S; Chaudhri I; Allam E; Baxter L; Abo Freikha S; Hoestlandt C; Lara C; Hajjeh R; Munier A
Vaccine; 2015 May; 33 Suppl 1():A182-91. PubMed ID: 25919159
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
Melegaro A; Edmunds WJ
Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
[TBL] [Abstract][Full Text] [Related]
37. Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option.
Dorji K; Phuntsho S; Pempa ; Kumluang S; Khuntha S; Kulpeng W; Rajbhandari S; Teerawattananon Y
Vaccine; 2018 Mar; 36(13):1757-1765. PubMed ID: 29478752
[TBL] [Abstract][Full Text] [Related]
38. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
Hoshi SL; Kondo M; Okubo I
PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
[TBL] [Abstract][Full Text] [Related]
39. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.
Kuhlmann A; von der Schulenburg JG
Eur J Health Econ; 2017 Apr; 18(3):273-292. PubMed ID: 26905404
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China.
Zhao D; Gai Tobe R; Cui M; He J; Wu B
Vaccine; 2016 Dec; 34(50):6158-6165. PubMed ID: 27838068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
